Home › Funds › MONTANOVA CAPITAL, LLC › AVBP
MONTANOVA CAPITAL, LLC position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
MONTANOVA CAPITAL, LLC reported holding 4,925,531 shares of AVBP (ARRIVENT BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$149.1M, representing 3.47% of its reported portfolio and ranking #6 among its reported holdings. MONTANOVA CAPITAL, LLC has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How MONTANOVA CAPITAL, LLC's AVBP position evolved
MONTANOVA CAPITAL, LLC first disclosed a stake in AVBP in Q1 2024 at 1,563,709 shares (US$27.9M). The position peaked in Q2 2026 at 4,515,531 shares, worth US$156.9M. Across 11 filings, MONTANOVA CAPITAL, LLC increased the stake 10 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,925,531 shares valued at US$149.1M — an increase of 410,000 shares quarter over quarter.. Notable position changes include a 46% increase in Q2 2025 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 1.56M | $27.93M | New |
| Q2 2024 | 1.71M | $31.77M | Add |
| Q3 2024 | 1.85M | $43.36M | Add |
| Q4 2024 | 2.25M | $59.83M | Add |
| Q1 2025 | 2.34M | $43.22M | Add |
| Q2 2025 | 3.41M | $74.30M | Add |
| Q3 2025 | 3.70M | $68.33M | Add |
| Q4 2025 | 4.11M | $82.61M | Add |
| Q1 2026 | 4.40M | $101.53M | Add |
| Q2 2026 | 4.52M | $156.87M | Add |
| Q3 2026 | 4.93M | $149.15M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC) is a Health Care company. 51 other funds we track also report a position in AVBP — the largest reported positions include INFINITUM ASSET MANAGEMENT, LLC (US$137.0M), Hillhouse Capital (HHLR Advisors) (US$119.0M), ORBIMED ADVISORS LLC (US$91.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- INFINITUM ASSET MANAGEMENT, LLC 4.52M sh · $136.98M · Q3 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $118.97M · Q3 2026
- ORBIMED ADVISORS LLC 3.03M sh · $91.67M · Q3 2026
- Octagon Capital Advisors LP 2.14M sh · $64.84M · Q3 2026
- Vivo Capital, LLC 1.79M sh · $54.11M · Q3 2026
- Sofinnova Investments, Inc. 1.70M sh · $51.38M · Q3 2026
- General Catalyst Group Management, LLC 1.49M sh · $45.26M · Q3 2026
- Logos Global Management LP 1.35M sh · $40.88M · Q3 2026
- Novo Holdings A/S 1.18M sh · $35.58M · Q3 2026
- HSG Holding Ltd 663.31K sh · $20.08M · Q3 2026
- Foresite Capital Management VI LLC 490.34K sh · $14.85M · Q3 2026
- Seven Fleet Capital Management LP 451.17K sh · $13.66M · Q3 2026
More on MONTANOVA CAPITAL, LLC
FAQ
How long has MONTANOVA CAPITAL, LLC held AVBP?
MONTANOVA CAPITAL, LLC has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is MONTANOVA CAPITAL, LLC's current position in AVBP?
As of Q3 2026, MONTANOVA CAPITAL, LLC holds 4.93M shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $149.15M, representing 3.47% of its reported portfolio and ranking #6.
Has MONTANOVA CAPITAL, LLC been buying or selling AVBP?
In the latest 13F filing (Q3 2026), MONTANOVA CAPITAL, LLC increased its position in AVBP. The position peaked in Q2 2026 at 4.52M shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), ORBIMED ADVISORS LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.